A range of political issues have impacted FDA initiatives vital to the agency’s effectiveness and stature, both at home and on the important global stage.

Domainex is collaborating with Parkinson’s UK for the development of small-molecule therapies targeting the neuroinflammation that is associated with Parkinson’s disease.

ABPI has responded to the publication of a white paper on ‘Levelling Up’ by the government of the United Kingdom.

Zetta Genomics has raised £2.5 million ($3.4 million) in new seed funding.

Janssen has submitted a MAA to the EMA for teclistamab as a treatment of relapsed or refractory multiple myeloma (RRMM).

pharmasol has completed the strategic merger with PharmaLex.

Pharming Group has announced positive results from the Phase II/III study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).

The UK’s NICE issued a Final Appraisal Document recommending marketing authorization for AstraZeneca’s chronic kidney disease treatment, Forxiga (dapagliflozin).

Although mRNA and viral vector vaccines have been top of mind for COVID-19 treatments, other technologies and treatments are emerging—along with new variants.

Eli Lilly and Company has entered into a research and collaboration agreement with Entos Pharmaceuticals to develop new therapeutics for treating neurologic disorders.

The global nature of the COVID-19 pandemic emphasizes the critical importance of expanded vaccination.

As company revenues are gaining a boost from COVID-19, the issue of pricing is being debated once more.

The process of reshaping inevitably leads to fresh insights.

Busy is good for business.

Arranta Bio will use Cytiva’s FlexFactory single-use manufacturing platform to produce mRNA vaccines.

Recipharm will build up its biologics service offering with the acquisition of GenIbet.

Metagenomi has successfully raised $175 million for use toward its research pipeline.

Both Pfizer and Moderna have started clinical trials for their respective Omicron COVID-19 variant vaccine.

The draft PREVENT Pandemic Act aims to secure supply chains, expand health data collection, and support access to vital medical products

IonSense’s DART-MS technology offers rapid drug analysis without the need for sample preparation.

Texcell North America’s new lab facility in Frederick, Md., will expand the CRO’s capabilities in R&D cell culture, viral clearance studies, and viral safety testing.

Refeyn’s SamuxMP enables routine quantification of empty/full AAV capsid ratios, even in smaller labs, to set a new standard in AAV characterization

Samsung Biologics has signed an agreement with Biogen to acquire Biogen’s 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to $2.3 billion.

PhoreMost has entered into separate collaboration agreements with Polaris Quantum Biotech and NeoCura Bio-Medical Technology to discover and develop novel cancer therapeutics.

BenchSci, a specialist in machine learning applications for novel medicine development, has completed a Series C financing round.

Scottish biotech engineering company, uFraction8, has successfully secured more than £2.5 million ($3.3 million) in new investment.

NICE has updated its Technology Appraisal Guidance TA599 for AstraZeneca’s Lokelma.

Catalent has expanded its Malvern, Pennsylvania, USA, and Dartford, UK, facilities to provide advanced containment capabilities for the micronization of highly potent drug compounds.